Los Angeles Capital Management LLC Makes New Investment in Immunome, Inc. (NASDAQ:IMNM)

Los Angeles Capital Management LLC bought a new stake in Immunome, Inc. (NASDAQ:IMNM) during the fourth quarter, Holdings Channel reports. The institutional investor bought 35,721 shares of the company’s stock, valued at approximately $379,000.

Several other hedge funds also recently modified their holdings of IMNM. Charles Schwab Investment Management Inc. raised its position in Immunome by 217.0% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 442,477 shares of the company’s stock valued at $6,469,000 after buying an additional 302,916 shares during the last quarter. Victory Capital Management Inc. grew its stake in shares of Immunome by 48.1% in the 3rd quarter. Victory Capital Management Inc. now owns 730,785 shares of the company’s stock worth $10,684,000 after acquiring an additional 237,497 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Immunome by 13.6% in the 3rd quarter. Geode Capital Management LLC now owns 1,207,455 shares of the company’s stock worth $17,657,000 after acquiring an additional 144,557 shares in the last quarter. Magnus Financial Group LLC raised its holdings in shares of Immunome by 107.8% in the fourth quarter. Magnus Financial Group LLC now owns 53,536 shares of the company’s stock valued at $569,000 after purchasing an additional 27,777 shares during the last quarter. Finally, Point72 Asset Management L.P. lifted its position in shares of Immunome by 22.2% during the third quarter. Point72 Asset Management L.P. now owns 470,647 shares of the company’s stock valued at $6,881,000 after purchasing an additional 85,580 shares in the last quarter. Hedge funds and other institutional investors own 44.58% of the company’s stock.

Insider Transactions at Immunome

In other news, CEO Clay B. Siegall acquired 150,000 shares of Immunome stock in a transaction on Friday, January 31st. The stock was acquired at an average cost of $7.75 per share, with a total value of $1,162,500.00. Following the completion of the acquisition, the chief executive officer now owns 669,636 shares in the company, valued at approximately $5,189,679. This trade represents a 28.87 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 8.60% of the stock is currently owned by company insiders.

Immunome Stock Performance

Shares of IMNM stock opened at $8.94 on Tuesday. The firm has a market cap of $713.21 million, a price-to-earnings ratio of -1.10 and a beta of 1.90. Immunome, Inc. has a 52 week low of $8.55 and a 52 week high of $30.96. The firm’s 50-day simple moving average is $10.29 and its two-hundred day simple moving average is $12.13.

Analyst Upgrades and Downgrades

IMNM has been the subject of a number of recent analyst reports. Piper Sandler reduced their price objective on shares of Immunome from $23.00 to $21.00 and set an “overweight” rating for the company in a research report on Thursday, November 14th. Wedbush reaffirmed an “outperform” rating and issued a $33.00 target price on shares of Immunome in a report on Monday, January 13th. Finally, Stephens initiated coverage on Immunome in a report on Friday, November 8th. They set an “overweight” rating and a $30.00 price target on the stock. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $28.60.

Immunome Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.